{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:43Z","timestamp":1787841343727,"version":"build-2784847793"},"reference-count":4,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.hemonc.2020.04.005","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T21:52:26Z","timestamp":1588888346000},"page":"353-354","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Ribociclib-Induced Radiation Recall Dermatitis Following Stereotactic Body Radiation Therapy"],"prefix":"10.4103","volume":"14","author":[{"given":"Ayah","family":"Erjan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmajeed","family":"Dayyat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20241211","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0167-8140(01)00328-0","article-title":"Characterizing the phenomenon of radiation recall dermatitis","volume":"59","author":"Camidge","year":"2001","journal-title":"Radiother Oncol"},{"key":"R2-12-20241211","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptorpositive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"key":"R3-12-20241211","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.ejca.2012.12.009","article-title":"Targeted therapy-induced radiation recall","volume":"49","author":"Levy","year":"2013","journal-title":"Eur J Cancer"},{"key":"R4-12-20241211","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/CAD.0b013e328333d679","article-title":"Radiation recall dermatitis by multi-targeted tyrosine kinase inhibitors:sunitinib and sorefenib","volume":"21","author":"Chung","year":"2010","journal-title":"Anticancer Drugs"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620300510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620300510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2020.04.005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:49:48Z","timestamp":1787838588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2020.04.005"}},"subtitle":["Case Report and Literature Review"],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":4,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2020.04.005","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}